Gossamer Bio Inc (GOSS)

Currency in USD
0.451
+0.019(+4.47%)
Closed·
0.450-0.001(-0.22%)
·
GOSS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4240.468
52 wk Range
0.3203.870
Key Statistics
Prev. Close
0.432
Open
0.429
Day's Range
0.424-0.468
52 wk Range
0.32-3.87
Volume
8.77M
Average Vol. (3m)
16.42M
1-Year Change
-45.6561%
Book Value / Share
-0.53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GOSS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.686
Upside
+717.23%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Gossamer Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $9.9M exceeded $4.25M forecast; EPS loss of $0.16 beat expected $0.19 loss
  • Stock rose 3.96% post-earnings; company maintains 'GOOD' financial health score per InvestingPro
  • Strong cash position of $257.9M; focus on pulmonary hypertension treatments
  • Top-line results from PROCERA Phase 3 study expected Feb 2026; SERENADA Phase 3 to start Q4 2025
  • Analysts forecast 83% revenue decline for FY2025 despite Q1 outperformance
Last Updated: 05/15/2025, 05:47 PM
Read Full Transcript

Compare GOSS to Peers and Sector

Metrics to compare
GOSS
Peers
Sector
Relationship
P/E Ratio
−0.6x−2.5x−0.5x
PEG Ratio
0.000.090.00
Price / Book
−0.9x5.3x2.6x
Price / LTM Sales
2.2x10.3x3.2x
Upside (Analyst Target)
131.5%46.0%47.6%
Fair Value Upside
Unlock3.3%6.1%Unlock

Analyst Ratings

3 Buy
5 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 3.686
(+717.23% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Hold---DowngradeMar 23, 2026
H.C. Wainwright
Buy5.00+1,008.65%10.00MaintainMar 06, 2026
Oppenheimer
Buy3.00+565.19%12.00MaintainMar 05, 2026
Goldman Sachs
Hold0.50+10.86%8.00MaintainFeb 25, 2026
Wedbush
Hold1.00+121.73%-DowngradeFeb 24, 2026

Earnings

Latest Release
Mar 17, 2026
EPS / Forecast
-0.21 / -0.19
Revenue / Forecast
13.8M / 7.52M
EPS Revisions
Last 90 days

GOSS Income Statement

People Also Watch

1.230
QNCX
-1.60%
3.30
BATL
-1.49%
1.36
UCAR
-9.93%
0.9708
PRSO
+6.08%
7.78
IBRX
+2.37%

FAQ

What Is the Gossamer Bio (GOSS) Stock Price Today?

The Gossamer Bio stock price today is 0.451 USD.

What Stock Exchange Does Gossamer Bio Trade On?

Gossamer Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Gossamer Bio?

The stock symbol for Gossamer Bio is "GOSS."

What Is the Gossamer Bio Market Cap?

As of today, Gossamer Bio market cap is 104.440M USD.

What Is Gossamer Bio's Earnings Per Share (TTM)?

The Gossamer Bio EPS (TTM) is -0.746.

When Is the Next Gossamer Bio Earnings Date?

Gossamer Bio will release its next earnings report on May 12, 2026.

From a Technical Analysis Perspective, Is GOSS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Gossamer Bio Stock Split?

Gossamer Bio has split 0 times.

How Many Employees Does Gossamer Bio Have?

Gossamer Bio has 162 employees.

What is the current trading status of Gossamer Bio (GOSS)?

As of Apr 15, 2026, Gossamer Bio (GOSS) is trading at a price of 0.451 USD, with a previous close of 0.432 USD. The stock has fluctuated within a day range of 0.424 USD to 0.468 USD, while its 52-week range spans from 0.320 USD to 3.870 USD.

What Is Gossamer Bio (GOSS) Price Target According to Analysts?

The average 12-month price target for Gossamer Bio is 3.686 USD, with a high estimate of 15 USD and a low estimate of 0.3 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +717.23% Upside potential.

What Is the GOSS Premarket Price?

GOSS's last pre-market stock price is 0.420 USD. The pre-market share volume is 34,000.000, and the stock has decreased by -0.012, or -2.780%.

What Is the GOSS After Hours Price?

GOSS's last after hours stock price is 0.450 USD, the stock has decreased by -0.001, or -0.220%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.